Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/s41586-021-03594-0 http://scihub22266oqcxt.onion/10.1038/s41586-021-03594-0 33971664!8528238!33971664     free     free     free Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Nature 2021 ; 594 (7864): 553-559 Nephropedia Template TP {{tp|p=33971664|t=2021. Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses |pdf=|usr=}}{{33971664}} gab.com Text Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses JO: Nature http://www.kidney.de/pget.php?&tw=1&pmid=33971664 #FOAvip Betacoronaviruses caused the outbreaks of severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome, as well as the current pandemic of SARS coronavirus 2 (SARS-CoV-2)(1-4). Vaccines that elicit protective immunity against SARS-CoV-2 and betacoronaviruses that circulate in animals have the potential to prevent future pandemics. Here we show that the immunization of macaques with nanoparticles conjugated with the receptor-binding domain of SARS-CoV-2, and adjuvanted with 3M-052 and alum, elicits cross-neutralizing antibody responses against bat coronaviruses, SARS-CoV and SARS-CoV-2 (including the B.1.1.7, P.1 and B.1.351 variants). Vaccination of macaques with these nanoparticles resulted in a 50% inhibitory reciprocal serum dilution (ID(50)) neutralization titre of 47,216 (geometric mean) for SARS-CoV-2, as well as in protection against SARS-CoV-2 in the upper and lower respiratory tracts. Nucleoside-modified mRNAs that encode a stabilized transmembrane spike or monomeric receptor-binding domain also induced cross-neutralizing antibody responses against SARS-CoV and bat coronaviruses, albeit at lower titres than achieved with the nanoparticles. These results demonstrate that current mRNA-based vaccines may provide some protection from future outbreaks of zoonotic betacoronaviruses, and provide a multimeric protein platform for the further development of vaccines against multiple (or all) betacoronaviruses. Twit Text FOAVip Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses ????Nature http://www.kidney.de/pget.php?&tw=1&pmid=33971664 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33971664 #FOAvip English Wikipedia <ref>{{Cite pmid|33971664}}</ref> Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses #MMPMID33971664 Saunders KO; Lee E; Parks R; Martinez DR; Li D; Chen H; Edwards RJ; Gobeil S; Barr M; Mansouri K; Alam SM; Sutherland LL; Cai F; Sanzone AM; Berry M; Manne K; Bock KW; Minai M; Nagata BM; Kapingidza AB; Azoitei M; Tse LV; Scobey TD; Spreng RL; Rountree RW; DeMarco CT; Denny TN; Woods CW; Petzold EW; Tang J; Oguin TH 3rd; Sempowski GD; Gagne M; Douek DC; Tomai MA; Fox CB; Seder R; Wiehe K; Weissman D; Pardi N; Golding H; Khurana S; Acharya P; Andersen H; Lewis MG; Moore IN; Montefiori DC; Baric RS; Haynes BF Nature 2021[Jun]; 594 (7864): 553-559 PMID33971664show ga Betacoronaviruses caused the outbreaks of severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome, as well as the current pandemic of SARS coronavirus 2 (SARS-CoV-2)(1-4). Vaccines that elicit protective immunity against SARS-CoV-2 and betacoronaviruses that circulate in animals have the potential to prevent future pandemics. Here we show that the immunization of macaques with nanoparticles conjugated with the receptor-binding domain of SARS-CoV-2, and adjuvanted with 3M-052 and alum, elicits cross-neutralizing antibody responses against bat coronaviruses, SARS-CoV and SARS-CoV-2 (including the B.1.1.7, P.1 and B.1.351 variants). Vaccination of macaques with these nanoparticles resulted in a 50% inhibitory reciprocal serum dilution (ID(50)) neutralization titre of 47,216 (geometric mean) for SARS-CoV-2, as well as in protection against SARS-CoV-2 in the upper and lower respiratory tracts. Nucleoside-modified mRNAs that encode a stabilized transmembrane spike or monomeric receptor-binding domain also induced cross-neutralizing antibody responses against SARS-CoV and bat coronaviruses, albeit at lower titres than achieved with the nanoparticles. These results demonstrate that current mRNA-based vaccines may provide some protection from future outbreaks of zoonotic betacoronaviruses, and provide a multimeric protein platform for the further development of vaccines against multiple (or all) betacoronaviruses. |*Pandemics[MESH] |Adjuvants, Immunologic[MESH] |Administration, Intranasal[MESH] |Animals[MESH] |Antibodies, Neutralizing/*immunology[MESH] |Betacoronavirus/*immunology[MESH] |COVID-19 Vaccines/immunology[MESH] |COVID-19/epidemiology/*immunology/*prevention & control[MESH] |Common Cold/immunology/*prevention & control/virology[MESH] |Cross Reactions/*immunology[MESH] |Disease Models, Animal[MESH] |Female[MESH] |Humans[MESH] |Macaca/immunology[MESH] |Male[MESH] |Models, Molecular[MESH] |Nanoparticles/chemistry[MESH] |SARS-CoV-2/immunology[MESH] |Spike Glycoprotein, Coronavirus/chemistry/immunology[MESH] |Trachea[MESH] |Vaccination[MESH]Neutralizing antibody vaccine for pandemic and pre-emergent coronaviru(epmc).pdf DeepDyve Pubget Overpricing